Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial. [electronic resource]
Producer: 20190409Description: 812-824 p. digitalISSN:- 1474-5488
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Biomarkers, Tumor -- analysis
- Breast Neoplasms -- chemistry
- Female
- Furans -- administration & dosage
- Humans
- Ketones -- administration & dosage
- Maximum Tolerated Dose
- Middle Aged
- Neoplasm Metastasis
- Peptides, Cyclic -- administration & dosage
- Receptor, ErbB-2 -- analysis
- Receptors, CXCR4 -- antagonists & inhibitors
- Spain
- Time Factors
- Treatment Outcome
- United States
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.